Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.
- 1 November 1996
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 98 (9) , 2109-2119
- https://doi.org/10.1172/jci119017
Abstract
The progressive inflammatory process found in transforming growth factor beta1 (TGF-beta1)-deficient mice is associated with several manifestations of autoimmunity, including circulating antibodies to nuclear antigens, immune complex deposition, and increased expression of both class I and class II major histocompatibility complex (MHC) antigens. The contribution of MHC class II antigens to the genesis of this phenotype has been determined by crossing the TGF-beta1-null [TGF-beta1(-/-)] genotype into the MHC class II-deficient [MHC-II(-/-)] background. Mice homozygous for both the TGF-beta1 null allele and the class II null allele [TGF-beta1(-/-);MHC-II(-/-)] are without evidence of inflammatory infiltrates, circulating autoantibodies, or glomerular immune complex deposits. Instead, these animals exhibit extensive extramedullary hematopoiesis with progressive splenomegaly and adenopathy, surviving only slightly longer than TGF-beta1(-/-);MHC-II(+/+) mice. The role of CD4+ T cells, which are also absent in MHC class II-deficient mice, is directly demonstrated through the administration of anti-CD4 monoclonal antibodies in class II-positive, TGF-beta1(-/-) mice. The observed reduction in inflammation and improved survival emphasize the significance of CD4+ cells in the pathogenesis of the autoimmune process and suggest that the additional absence of class II antigens in TGF-beta1(-/-);MHC-II(-/-) mice may contribute to their extreme myeloid metaplasia. Thus, MHC class II antigens are essential for the expression of autoimmunity in TGF-beta1-deficient mice, and normally may cooperate with TGF-beta1 to regulate hematopoiesis.Keywords
This publication has 45 references indexed in Scilit:
- Transforming growth factor beta: the good, the bad, and the ugly.The Journal of Experimental Medicine, 1994
- Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice.The Journal of Experimental Medicine, 1994
- A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitisNature, 1994
- Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta.The Journal of Experimental Medicine, 1993
- Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain.The Journal of Experimental Medicine, 1992
- Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory diseaseNature, 1992
- TGF‐beta inhibits proliferation of and promotes differentiation of human promonocytic leukemia cellsJournal of Cellular Physiology, 1992
- Modulation of the Immune Response by Transforming Growth Factor BetaInternational Archives of Allergy and Immunology, 1992
- Stochastic control of anti-Sm autoantibodies in MRL/Mp-lpr/lpr mice.Journal of Clinical Investigation, 1987
- Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4.The Journal of Experimental Medicine, 1985